Acura takes $200K loan as bankruptcy looms without new funding by September
What's the deal? Acura PharmaceuticalsDealroom has a profile for this one. Try Dealroom → (ACUR) received a $200,000 loan from Abuse Deterrent Pharma, LLC on August 14, 2026, applying the proceeds to day-to-day operations. The financing lifts the principal under its amended secured promissory note to $11,094,279, with roughly $1,290,000 in accrued interest.
The terms: The note carries 5.25% interest, rising to a 7.5% default rate. The small size and use — funding routine operations — underscore Acura's dependence on short-term financing from AD Pharma.
What could go wrong? Acura warned that without additional financing by late September 2026, it would need to scale back operations, furlough or lay off staff, or potentially terminate operations and seek bankruptcy protection — risking a complete loss of shareholder value. Even with new funding, the company cautioned the capital may be insufficient to reach a point where product revenues can sustain the business.
What's the endgame? Acura is a specialty pharmaceutical company developing pain management and opioid products with proprietary LIMITx and Impede technologies designed to deter abuse. Its lead candidate, LTX-03, is a hydrocodone and acetaminophen combination formulated with LIMITx.
Why now? The company's operations depend on meeting US Food and Drug Administration requirements and securing enough capital to bridge the gap until product revenues can support growth. Regulatory timelines and funding availability leave little room for delay.
The signal: A $200,000 loan applied to daily costs, against an $11 million debt load and an explicit going-concern warning, points to a company running on fumes. For stakeholders, the question is no longer growth but survival past September.
Read more: TipRanks
Image credit: nickgraywfu
